-- Continuing to solidify their position as a global leader in the field of Glycoengineering, CD BioGlyco is proud to launch its next generation Antibody Glycan Remodeling Service, which provides researchers and pharmaceutical developers with a powerful platform for producing targeted glycoforms of their antibodies’ Fc region. By using cutting-edge chemoenzymatic technology powered by glycoengineering, this service allows for the simultaneous creation of multiple human IgG antibodies, which can be generated with specific G0, G1, G2 or G2S2 glycoforms (glycosylation patterns).
Unlocking the Potential of Fc Glycan Remodeling
The Fc region of IgG antibodies contains a conserved asparagine (Asn297) site, which is naturally glycosylated. These N-glycans play a pivotal role in determining antibody effector functions, including binding to Fc receptors and mediating immune responses. By carefully remodeling these glycans, CD BioGlyco allows for the development of antibodies with optimized functional properties, improved efficacy, and minimized adverse immune reactions.
Precision Glycoengineering Approaches
CD BioGlyco offers a range of methods to achieve site-specific glycan remodeling:
l Cell Glycoengineering: During protein expression, it is possible to develop and obtain antibodies with specific glycoforms by altering host cells, environmental conditions, or biosynthetic pathways. Targeted glycan modifications can be achieved through genetic or chemical means.
l Chemoenzymatic Glycoengineering: Existing Fc glycans are trimmed to core GlcNAc residues using specific endoglycosidases. Then, glycosynthase catalyzes the attachment of specific glycans, such as G0, G1, G2, or G2S2, resulting in a homogeneous population of antibodies.
l Site-Specific Antibody-Drug Conjugation (ADC): Fc glycan remodeling supports the generation of well-defined ADCs by providing uniform attachment sites for cytotoxic payloads, enhancing both structural consistency and therapeutic potential.
Workflow and Quality Assurance
The remodeling process begins with a detailed consultation to shape therapeutic goals alongside specific characteristics of the antibodies. After enzymatic trimming and glycan transglycosylation, remodeled antibodies undergo a thorough purification and quality control process. Mass Spectrometry (MS) and High-Performance Liquid Chromatography (HPLC) are employed to identify the glycoform and evaluate the structure, ensuring consistent and quality results.
Applications Across Therapeutics and Research
CD BioGlyco’s Antibody Glycan Remodeling services support multiple areas:
Therapeutic Antibody Development: Optimize efficacy and safety for antibodies targeting cancer, autoimmune, infectious, and inflammatory diseases.
Drug Discovery and Optimization: Rapidly screen and refine antibody candidates with superior functional properties.
Fundamental Glycobiology Research: Investigate structure-function relationships of antibody glycans to advance understanding of immunological processes and disease mechanisms.
A Trusted Partner in Glycoengineering
CD BioGlyco leverages its state-of-the-art platform and years of experience to deliver precise and consistent modifications to your antibody glycans. Researchers can now access homogeneous glycoforms tailored to their experimental or therapeutic goals, enabling more effective drug development and mechanistic studies.
To learn more about how CD BioGlyco’s Antibody Glycan Remodeling service can enhance your antibody research, visit our service page for consultation and detailed service information. You can also download the Glycan Remodeling Service brochure (PDF) for a detailed overview of our platform and workflow.
Contact Info:
Name: Anna Bryan
Email: Send Email
Organization: CD BioGlyco
Website: https://www.bioglyco.com
Release ID: 89179827
Google
RSS